RP05129 / Risen (Suzhou) Biosci - LARVOL DELTA

Title: Discovery of a Small-Molecule Inhibitor of ADAR1 for Cancer Immunotherapy (ACCESSWIRE) - "Risen Pharma...announced poster presentations...at the American Association for Cancer Research (AACR) Annual Meeting 2025....Key findings in the presentation:...RP05129 demonstrated the ability to downregulate ADAR1 editing activity and trigger downstream interferon-β activation in an ADAR1 dependent manner. High-resolution co-crystal structures of ADAR1 with inhibitor RP05129 or its analogs were solved in-house to guide SAR study. RP05129 and its analogs hold promise for enhancing the efficacy of immune-based therapies in cancers that are dependent on ADAR1."

Preclinical • Oncology